Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Shawn P Zinnen

TitleElectronic Research Admin
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-BioChem&Molecular Genetics

    Collapse Research 
    Collapse research activities and funding
    F32GM017795     (ZINNEN, SHAWN PATRICK)Mar 12, 1996
    Role: Principal Investigator

    R43CA167964     (ZINNEN, SHAWN PATRICK)Jun 1, 2013 - May 31, 2015
    Novel Vitamin B6 based prodrugs of gemcitabine
    Role: Principal Investigator

    R43CA203166     (ZINNEN, SHAWN PATRICK)Feb 1, 2016 - Jan 31, 2017
    Novel Bone-Targeting Combination Therapy for Osteosarcoma
    Role: Principal Investigator

    R44CA203166     (ZINNEN, SHAWN PATRICK)Feb 1, 2016 - Aug 31, 2019
    Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II
    Role: Principal Investigator

    R43AI127359     (ZINNEN, SHAWN PATRICK)Aug 7, 2017 - Jul 31, 2019
    Bone Targeted Antibiotics
    Role: Principal Investigator

    R44CA232963     (GLODE, MIKE)Sep 1, 2018 - Aug 31, 2019
    DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zinnen SP, Karpeisky A, Von Hoff DD, Plekhova L, Alexandrov A. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar; 24(3):303-e102. PMID: 30413669.
      View in: PubMed
    2. Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting. Bone Rep. 2018 Dec; 9:47-60. PMID: 29992180.
      View in: PubMed
    3. Healey GD, Lockridge JA, Zinnen S, Hopkin JM, Richards I, Walker W. Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6. PLoS One. 2014; 9(2):e90338. PMID: 24587331; PMCID: PMC3937390.
    4. Healey GD, Zinnen S, Lockridge JA, Richards I, Evans N, Walker W. Identification of small interfering RNA targeting Signal Transducer and Activator of Transcription 6: Characterisation and selection of candidates for pre-clinical development. J RNAi Gene Silencing. 2010 Aug 25; 6(2):401-10. PMID: 20927184; PMCID: PMC2943664.
    5. Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lönnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, Karpeisky A, Lingle WL. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul; 47(1):12-22. PMID: 20233612; PMCID: PMC2892200.
    6. Ora M, Lönnberg T, Florea-Wang D, Zinnen S, Karpeisky A, Lönnberg H. Bisphosphonate derivatives of nucleoside antimetabolites: hydrolytic stability and hydroxyapatite adsorption of 5'-beta,gamma-methylene and 5'-beta,gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine. J Org Chem. 2008 Jun 06; 73(11):4123-30. PMID: 18473440.
      View in: PubMed
    7. Lively TN, Kossen K, Balhorn A, Koya T, Zinnen S, Takeda K, Lucas JJ, Polisky B, Richards IM, Gelfand EW. Effect of chemically modified IL-13 short interfering RNA on development of airway hyperresponsiveness in mice. J Allergy Clin Immunol. 2008 Jan; 121(1):88-94. PMID: 17936889.
      View in: PubMed
    8. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005 Aug; 23(8):1002-7. PMID: 16041363.
      View in: PubMed
    9. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA, Zinnen S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005 Jun; 41(6):1349-56. PMID: 15880588.
      View in: PubMed
    10. Zinnen SP, Domenico K, Wilson M, Dickinson BA, Beaudry A, Mokler V, Daniher AT, Burgin A, Beigelman L. Selection, design, and characterization of a new potentially therapeutic ribozyme. RNA. 2002 Feb; 8(2):214-28. PMID: 11911367; PMCID: PMC1370244.
    Zinnen's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description

    Copyright © 2019 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)